Please use this identifier to cite or link to this item:
|Title:||Affinity of cholecystokinin receptor antagonists for the gastrin-binding protein.||Austin Authors:||Rorison, K A;Yang, Z;Baldwin, Graham S||Affiliation:||Department of Surgery, University of Melbourne, Austin and Repatriation Medical Centre, Austin Campus, Studley Rd., Heidelberg, Australia||Issue Date:||24-Jan-2000||Publication information:||European Journal of Pharmacology; 388(1): 9-15||Abstract:||A 78 kDa gastrin-binding protein is a likely target for the anti-proliferative effects of the cholecystokinin (CCK) receptor antagonists D,L-4-benzamido-N,N-dipropylglutaramic acid (proglumide) and N-4-chlorobenzoyl-L-tryptophan (benzotript) on colorectal carcinoma cell lines [Baldwin, G.S., 1994. Antiproliferative gastrin/cholecystokinin receptor antagonists target the 78-kDa gastrin-binding protein. Proc. Natl. Acad. Sci. USA 91, 7593-7597.]. Definition of the physiological role of the gastrin-binding protein has been hampered by the very low affinity of benzotript for the gastrin-binding protein. Benzotript analogues were therefore tested for their ability to inhibit the binding of iodinated gastrin to the gastrin-binding protein. The affinity of the most potent analogue (the D-isomer of benzotript, CR 665) was similar to the value reported previously for the L-isomer. In order to isolate more potent binding inhibitors, several selective CCK receptor antagonists were also tested as inhibitors of the binding of gastrin to the gastrin-binding protein. The affinity of the most potent binding inhibitor PD 149164 (benzenebutanoic acid, 4-fluoro-!b/-[[3-(1H-indol-3-yl)-2-methyl-1-oxo-2-[[(tricyclo-[3.3 .1. 1(3,7)]dec-2-yloxy)carbonyl]amino]propyl]amino]-, [R-(R*,S*)]-) was approximately 10-fold higher than the L-isomer of benzotript. PD 149164 may serve as the lead compound for the future development of more potent and selective gastrin-binding protein inhibitors.||Gov't Doc #:||10657541||URI:||http://ahro.austin.org.au/austinjspui/handle/1/9203||Journal:||European Journal of Pharmacology||URL:||https://pubmed.ncbi.nlm.nih.gov/10657541||Type:||Journal Article||Subjects:||Adamantane.analogs & derivatives.pharmacology
Carrier Proteins.antagonists & inhibitors.isolation & purification.metabolism
Mitochondrial Trifunctional Protein
Receptors, Cholecystokinin.agonists.antagonists & inhibitors
|Appears in Collections:||Journal articles|
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.